Bacteriophage therapy: Practicability and clinical need meet in the multidrug-resistance era

Future Microbiology

Volumn 7, Issue 7, 2012, Pages 797-799

  Harper, David R ^a   Morales, Sandra ^b  

^a AmpliPhi Biosciences Corp   (United Kingdom)

^b Special Phage Services   (Australia)

Author keywords

antibiotic resistance; bacteriophage; bacteriophage therapy; clinical trial

Indexed keywords

ANTIMICROBIAL THERAPY; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; ESCHERICHIA COLI INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS;

ANIMALS; BACTERIAL INFECTIONS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84864368996     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.58     Document Type: Review

References (18)

1. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature 472, 32 (2011).
2. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int. J. Antimicrob. Agents 39(4), 295-299 (2012).
3. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 17(2), 66-72 (2009).
4. Duckworth DH. Who discovered bacteriophage? Bacteriol. Rev. 40, 793-802 (1976).
5. Summers WC. Felix d'Herelle and the Origins of Molecular Biology. Yale University Press, CT, USA (1999).
6. Eaton M, Bayne-Jones S. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA 103(23), 1769-1776 (1934).
7. Krueger AP, Scribner EJ. The bacteriophage: Its nature and its therapeutic use. JAMA 116, 2160-2167 (1941).
8. Harper DR, Anderson J, Enright MC. Phage therapy: Delivering on the promise. Therapeutic Delivery 2(7), 935-947 (2011).
9. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-669 (2001).
10. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J. Gen. Microbiol. 128, 307-318 (1982). (Pubitemid 12159900)
11. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 37, 258-261 (1992).
12. Merrill CR, Biswas B, Carlton R et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl Acad. Sci. USA 93, 3188-3192 (1996). (Pubitemid 26125592)
13. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: Results of a Phase I safety trial. J. Wound Care 18, 237-243 (2009).
14. Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4(3), e4944 (2009).
15. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878 (2005). (Pubitemid 40917605)
16. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357 (2009).
17. Monk AB, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: Where are we now? Lett. Appl. Microbiol. 51(4), 363-369 (2010).
18. Verbeken G, Pirnay JP, De Vos D et al. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. (Warsz.) 60(3), 161-172 (2012).